Obstructive sleep apnea and longitudinal Alzheimer’s disease biomarker changes
- 22 February 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 42 (6)
Abstract
To determine the effect of self-reported clinical diagnosis of Obstructive Sleep Apnea (OSA) on longitudinal changes in brain amyloid-PET and CSF-biomarkers (Aβ42, T-tau and P-tau) in cognitively normal (NL), mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) elderly. Longitudinal study with mean follow-up time of 2.52±0.51 years. Data was obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. Participants included 516 NL, 798 MCI and 325 AD elderly. Main Outcomes were annual rate-of-change in brain amyloid-burden (i.e. longitudinal increases in florbetapir-PET uptake or decreases in CSF-Aβ42 levels); and tau-protein aggregation (i.e. longitudinal increases in CSF total-tau (T-tau) and phosphorylated-tau (P-tau)). Adjusted multi-level mixed effects linear regression models with randomly varying intercepts and slopes was used to test whether the rate-of-biomarker-change differed between participants with and without OSA. In NL and MCI groups, OSA+ subjects experienced faster annual increase in florbetapir uptake (B=.06, 95% CI .02, .11 and B=.08, 95% CI .05, .12 respectively) and decrease in CSF-Aβ42 levels (B=-2.71, 95% CI -3.11, -2.35 and B=-2.62, 95% CI -3.23, -2.03, respectively); as well as increases in CSF T-tau (B=3.68, 95% CI 3.31, 4.07 and B=2.21, 95% CI 1.58, 2.86, respectively) and P-tau (B=1.221, 95% CI, 1.02, 1.42 and, B=1.74, 95% CI 1.22, 2.27, respectively); compared to OSA- participants. No significant variations in the biomarker changes over time were seen in the AD group. In both NL and MCI, elderly, clinical interventions aimed to treat OSA are needed to test if OSA treatment may affect the progression of cognitive impairment due to AD.Keywords
Funding Information
- National Institutes of Health (T32HL129953, R01HL118624, R21AG049348, R21AG055002, R01AG056031, R01AG022374, R21AG059179, R01AG056682, P30AG008051, 1R01AG056531-01A1, 103952/Z/14/Z)
- National Institute on Aging
- National Heart, Lung, and Blood Institute
- American Sleep Medicine Foundation
- Foundation for Research in Sleep Disorders
- American Thoracic Society Foundation
- Friedman Brain Institute
- Wellcome Trust
This publication has 57 references indexed in Scilit:
- Obstructive sleep apnea treatment, slow wave activity, and amyloid‐βAnnals of Neurology, 2018
- Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without DementiaJAMA Neurology, 2018
- Obstructive sleep apnea decreases central nervous system–derived proteins in the cerebrospinal fluidAnnals of Neurology, 2016
- The Preclinical Alzheimer Cognitive CompositeJAMA Neurology, 2014
- Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloidAnnals of Neurology, 2013
- Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's diseaseJournal of the Neurological Sciences, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Midlife and Late-Life Obesity and the Risk of DementiaArchives of Neurology, 2009
- Depression as a Risk Factor for Alzheimer DiseaseArchives of Neurology, 2003
- Brain Infarction and the Clinical Expression of Alzheimer DiseaseThe Nun StudyJAMA, 1997